Sectoral Asset Management invests in Sweden's Aprea AB
Swedish pharmaceutical development company Aprea AB has raised US$51 million (SEK 437 million) is a Series B financing. The round was co-led by U.S. venture capital firms Versant Ventures and 5AM Ventures, and was joined by Canadian healthcare investor Sectoral Asset Management, among others. Aprea will use the funds for clinical development of its anti-cancer compound, which targets tumor suppressor proteins. Aprea is a portfolio company of Swedish life sciences investment firm Karolinska Development AB. Last August, Sectoral and Knight Therapeutics Inc invested in U.S.-based biotechnology company Advaxis Inc.
10 March 2016•4 mins read
